Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A
Medical Polyclinic, University Hospital Basel, Switzerland.
Hepatology. 1995 Sep;22(3):774-9.
Forty-five extrahepatic bile duct carcinomas (i.e., tumors of the region proximal to the duct junction, including Klatskin tumors, tumors of the lower mid-region, and tumors of the ampulla of Vater) and 11 gallbladder carcinomas were immunohistochemically examined for p53 protein expression, using the DO-7 monoclonal (mAb) and the CM-1 polyvalent (pAb) antibodies and an antigen retrieval method. Because the DO-7 mAb was found to be significantly more reliable than the CM-1 pAb in detecting p53 immunoreactivity, the immunohistochemical results obtained with the former antibody were used for comparing p53 protein immunoreactivity with tumor site, tumor grade, and survival of patients. Approximately one third (3 of 10) of the proximal tumors were found to express weak p53 immunopositivity, whereas moderate immunopositivity and higher rate (18 of 29) was observed in tumors of the lower mid-region. Finally, moderate and marked p53 immunopositivity was observed in tumors of the ampulla (5 of 6) and gallbladder (8 of 11). In tumors of the lower mid-region of the ampulla and the gallbladder, a significantly higher p53 positivity was noted in high-grade compared with low-grade neoplasms. For the cases in which complete follow-up was available (11 tumors of the low mid-region), median survival of patients with p53-negative tumors was 25.7 months, whereas survival of those with p53-positive tumors was 5.2 months.(ABSTRACT TRUNCATED AT 250 WORDS)
对45例肝外胆管癌(即胆管汇合处近端区域的肿瘤,包括Klatskin瘤、中下段肿瘤和Vater壶腹肿瘤)和11例胆囊癌进行免疫组织化学检查,以检测p53蛋白表达,采用DO-7单克隆抗体(mAb)、CM-1多价抗体(pAb)及抗原修复方法。由于发现DO-7 mAb在检测p53免疫反应性方面比CM-1 pAb显著更可靠,因此用前一种抗体获得的免疫组织化学结果用于比较p53蛋白免疫反应性与肿瘤部位、肿瘤分级及患者生存率。发现约三分之一(10例中的3例)近端肿瘤表达弱p53免疫阳性,而在中下段肿瘤中观察到中等免疫阳性且比例更高(29例中的18例)。最后,在壶腹肿瘤(6例中的5例)和胆囊肿瘤(11例中的8例)中观察到中等和显著的p53免疫阳性。在壶腹中下段和胆囊肿瘤中,高级别肿瘤的p53阳性率明显高于低级别肿瘤。对于有完整随访资料的病例(11例中下段肿瘤),p53阴性肿瘤患者的中位生存期为25.7个月,而p53阳性肿瘤患者的生存期为5.2个月。(摘要截短至250字)